We have shown previously that the tissue factor pathway inhibitor-2 (TFPI-2), a broad range proteinase inhibitor, is highly expressed in low-grade gliomas, but, minimally expressed or undetectable in glioblastomas, and that enforced expression of this gene reduces the invasive properties of brain tumor cells. Here, we examined the role of promoter methylation as a mechanism of TFPI-2 gene silencing. In SNB19 glioblastoma cells, which have no detectable TFPI-2 expression, 5-aza-2 0 -deoxycytidine (5aC), an inhibitor of DNA methyltransferase, induced TFPI-2 mRNA in a dose-dependent manner. Trichostatin A (TSA), the histone deacetylase (HDAC) inhibitor, by itself, was more efficient than 5aC in inducing TFPI-2 transcripts, and the 5aC þ TSA combination resulted in highly synergistic reactivation of the gene, both at the transcript and protein levels. In Hs683 glioma cells, which express the TFPI-2 gene at high levels, transfection of the in vitro methylated TFPI-2 promoter constructs resulted in a drastic decrease of promoter activity compared to the unmethylated promoter. Further, the methylation-specific PCR in SNB19 and Hs683 cells showed that TFPI-2 gene repression was closely linked with methylation of the CpG islands in the promoter. Finally, the chromatin immunoprecipitation assays in SNB19 cells showed that the methylated and repressed TFPI-2 promoter was associated with the methyl-CpG binding protein 2 (MeCP2), and that gene reactivation resulted in the loss of MeCP2 from this site. These studies establish that TFPI-2 is transcriptionally silenced through promoter methylation in SNB19 cells.
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Introduction
Tissue factor pathway inhibitor-2 (TFPI-2), also known as matrix-associated serine protease inhibitor (MSPI) and placental protein 5 (PP5), is a novel protease inhibitor of 32-33 kDa that has three kunitz-type proteinase inhibitor domains homologous to TFPI (Bauer et al., 1994; Iino et al., 1998; Cameron et al., 1999; Rao et al., 2001) . Most of the TFPI-2 protein is associated with the extracellular matrix (Kaludov and Wolffe, 2000; Rao et al., 1998) . TFPI-2 inhibits trypsin, plasmin, chymotrypsin, cathepsin G, plasma kallikerin and factor VIIa-tissue factor complex but not uPA, tissue plasminogen activator (tPA), or thrombin (Bauer et al., 1994; Konduri et al., 2001a Konduri et al., , 2002 . The TFPI-2 gene has been mapped to chromosome 6q22 by fluorescence in situ hybridization (Petersen et al., 1996; Miyagi et al., 1996) . The recombinant TFPI-2 inhibits plasmin regardless of whether the enzyme was associated with tumor cells or with ECM, and inhibited matrix degradation and matrigel invasion by HT-1080 fibrosarcoma cells (Konduri et al., 2001b) .
The ability of TFPI-2 to curtail and regulate the various proteolytic activities associated with the ECM has great relevance to tumor invasion and metastasis. This is particularly true for malignant brain tumors because of their tendency to reside within the tissue of origin, and extensive studies from our laboratory have provided evidence for the involvement of a variety of proteases including the serine, metallo, and cysteine proteases in glioma invasion into normal brain tissue (Miyagi et al., 1994; McQueen et al., 1998; Lakka et al., 2000) .
Our previous studies showed that human glioma cells exhibit a differential pattern of TFPI-2 expression, with the higher grade glioms (astrocytomas and glioblastoma multiforme) showing no expression at all compared to the markedly higher levels of its expression observed in lower grade brain tumors (Miyazaki et al., 1994) . These results suggest that repression of TFPI-2 gene may be an important event that contributes to glioma progression as well as its malignant and invasive phenotype. In support of this notion, we observed that an enforced expression of TFPI-2 or its downregulation through an antisense approach caused a decrease or increase, respectively, in the invasive behavior of glioma cells (Nan et al., 1997) . We have isolated 3.8 kb TFPI-2 genomic fragment that contains 5 0 flanking region of TFPI-2 gene from the Hs683 glioblastoma cell line. Using reporter gene analysis in human glioblastoma cells, we have mapped a fragment of 670 bp that has high promoter activity. This promoter region has a high G þ C content, contains potential SP1 and AP1 binding motifs and lacks canonical TATA and CAAT boxes immediately upstream of the major transcriptional initiation site. With this background, the major aim of the current study was to define the molecular mechanisms that underlie the silencing of the TFPI-2 gene in human glioblastomas.
In human cancers including gliomas, the CpG island methylation occurs aberrantly and is associated with the inappropriate silencing of tumor suppressor genes and other genes that function in the suppression of the malignant phenotype. Methylation-mediated silencing contributes to malignant progression at several levels and has been implicated in the inactivation of genes involved in tumor suppression (e.g. Rb, VHL, and p16 INK4 ), the regulation of DNA repair and genome integrity (e.g. MLH1, MGMT, BRCA1), and the suppression of metastases (e.g. CDH1 and TIMP3) (Rao et al., 1995 (Rao et al., , 2001 Esteller et al., 2001) . In most of these cases, hypermethylation of the CpG islands present in the promoter region is associated with the loss of gene expression in tumor-derived cell lines and primary tumors relative to the normal somatic cells.
In contrast, the transcriptionally active chromatin is characterized by the enrichment of hyperacetylated histones and is generally associated with hypomethylated chromatin (Bauer et al., 1994; McQueen et al., 1998) The mechanisms underlying the correlation between DNA methylation and histone deacetylation in the control of gene expression have been recently established (Ng and Bird et al., 2000; Nan et al., 1997) . As the TFPI-2 promoter harbors dense CpG-rich sequence (Kamei et al., 2001) , we hypothesized that hypermethylation of the TFPI-2 gene promoter might be responsible for its inactivation in glioblastomas. Different lines of evidence obtained here clearly points to the paramount role of the 5 0 CpG methylation in glioma repression of the TFPI-2 gene.
Results
Reactivation of the TFPI-2 gene in SNB 19 glioblastoma following inhibition of DNA cytosine methyltransferase
The promoter of the TFPI-2 gene has dense CpG islands, and our initial studies involved the use of 5-azacytidine (5aC) to inhibit the activity of DNA methyltransferase (DNMT) and investigating the reactivation of the TFPI-2 gene in SNB19 cells. Genespecific primers were used in PCR reaction. Tumor cells in their exponential growth phase were treated with 2.5, 5, and 10 mm of 5aC for 3 days, and reverse transcriptase-polymerase chain reaction (RT-PCR) was performed to measure the expression of TFPI-2 gene transcripts. We observed a gradual and dose-dependent increase of TFPI-2 expression, with maximal gene activation at 10 mm under these conditions (Figure 1 ). Trypan blue exclusion assay showed that over 85% of the cells were viable and adherent after exposure to 5aC (azacitidine) at its highest concentration (5 mM for 3 days). The cell viability was similar in all four samples. These results suggest that apoptotic biochemical pathways were not involved in the reactivation of the TFPI-2 gene.
CpG methylation and HDAC operate in synergy to maintain the transcriptional silencing of the TFPI-2 gene in SNB19 cells
In view of the close physical association between the methyl CpG-binding proteins and the HDAC in chromatin remodeling and transcription processes, we examined the possibility of an additive or synergistic relation between these components. SNB 19 (2 Â 10 6 ) cells were plated and treated with 5 mm of 5aC for 3 days, followed by a short-term exposure (20 h) to 0.5 mm of trichostatin A (TSA), an established inhibitor of HDAC. RT-PCR and Western blot analyses were performed to determine the extent of gene expression. Interestingly, TSA treatment alone (5 mm for 20 h) induced significant levels of TFPI-2 gene transcripts than 5aC (Figure 2 ). Although the difference appears to be small on the gel, densitometric scanning of the bands revealed a significant difference between TSA and 5aC treatment (data not shown). Western analysis under these conditions showed that the production of the TFPI-2 protein in the ECM (25 ml from each sample) was highly enhanced, particularly in the 5aC þ TSA combination ( Figure 3 ). The triplet bands represent the differentially glycosylated forms of this protein (Rao et al., 1995) . Collectively, these data indicate that the DNA methylation machinery of which the histone deacetylase is a major component work together to inactivate TFPI-2 expression in SNB19 cells. RT-PCR analysis of TFPI-2 expression in SNB19 cells after 5aC treatment. SNB19 cells were treated with different concentrations of 5aC (2.5, 5, and 10 mm). After treatment, total RNA was isolated and 2 mg of RNA was used for RT-PCR. 5aC treatment in SNB19 cells triggered an increased and gradual expression of TFPI-2 mRNA in a dose-dependent fashion. GAPDH primers were used to verify that an equal amount of protein is loading (lower panel)
Reporter activity is affected after in vitro methylation of the TFPI-2 promoter
Gene reporter activity assay was performed to see the effect of 5aC-treated SNB19 cells. As seen in Figure 4a , the luciferase activity was highest in wild-type construct transfected cells compared to SNB19 parental cells and SNB19 cells treated with 5aC. There was only minimal increase in luciferase activity in SNB19 5aC-treated cells when compared to parental cells. It is clear that demethylation induced by 5aC was shown to activate the endogenous TFPI-2 promoter. The reason for this is unclear. However, it is possible that the methylated promoter construct (being plasmid borne) is not subject to demethylation in a similar fashion as endogeneous promoter (present in chomatin) because of its episomal nature and differences in its ability to interact with the methyl CpG-binding proteins and/or the histone deacetylation machinery. Similar results have been observed in other methylation studies. Further to confirm the specific role of promoter methylation in the silencing of the TFPI-2 expression, the wild-type promoter and methylated promoter constructs were transfected into Hs683 and SNB19 cells and luciferase reporter assay was performed. The SssI methylase used for in vitro modification of the promoter construct is known to methylate most cytosines in the DNA sequence. We found that the reporter activity was drastically reduced MeCP2 expression in SNB 19 cells with or without 5aC, TSA, or both SNB 19 (2 Â 10 6 ) cells were plated and treated with 5 mm of 5aC for 3 days and later with 0.5 mm of TSA for 20 h. Equal amounts of proteins (50 mg) were loaded onto SDS-polyacrylamide gel electrophoresis (PAGE) gels and immunoblotted with anti MeCP2 antibody. Interestingly, there was no difference with or without 5aC, TSA, or in combination in SNB19 cells. These results demonstrate that inhibition of the DNA methyltransferase and histone deacetylases does not alter the MeCP2 protein levels in SNB19 cells ( Figure 5 ), and are relevant in light of the chromatin immunoprecipitation (ChIP) analysis described in the next section.
ChIP
The ChIP assays provide valuable information on the identity of proteins that interact directly or indirectly with the transcriptionally silent and activated gene sequences. ChIP assays were performed to amplify the gene promoter DNA bound to the MeCP2 protein in SNB19 cells treated with 5aC, TSA, or both, which were shown to activate the TFPI-2 gene to different extents (Figures 1-3) . Following the formaldehyde-induced in situ crosslinking of DNA-protein complexes, the samples were immunoprecipitated with an antibody specific to MeCP2, and the DNA recovered from the immunocomplexes fragments were amplified using primers for TFPI-2 promoter. In SNB19 cells (untreated) in which the gene remains repressed, MeCP2 bound to the promoter as evidenced by the appearance of a PCR fragment of expected size (Figure 6 ). In 5aC-and TSA-treated SNB19 cells, the intensity of the PCR band was less; however, it was undetectable in cells treated with 5aC þ TSA combination, suggesting the complete loss of the MeCP2 protein from the activated TFPI-2 promoter (Figure 6 ). These results correlate with the degree of gene activation obtained with each drug, and their combination, and are in complete agreement with the known association of the MeCP2 and histone deacetylase proteins with the methylated chromatin.
Methylation-specific PCR (MSP) analysis of the TFPI-2 promoter
For a direct demonstration of the TFPI-2 promoter methylation, we modified the SNB19 cell DNA with sodium bisulfate, and performed MSP analysis using appropriate primers that would detect the methylated and unmethylated states of the cellular DNA. In these experiments, SNB19 (2 Â 10 6 ) cells were exposed to 5aC, TSA, or both, DNA was isolated and modified to convert the unmethylated cytosines to uracil. CpG Ware primer design software (Serologicals Inc.) was used to design primers to distinguish the methylated or unmethylated sequences of the CpG-richTFPI-2 promoter in the bisulfite-modified DNA. The promoter sequence was also amplified in the unmodified DNA using the wild-type primers. With the SNB19-modified DNA as the template, the methylated primers yielded an amplified product while the unmethylated primer set did not, demonstrating the methylated status of the endogenous sequence (Figure 7a ). In contrast, in cells treated with 5aC þ TSA, the methylated primers failed to provide a PCR product; however the unmethylated primers resulted in a fragment of expected size, showing that the promoter became demethylated after the drug treatments. The results of MSP analysis in Hs683 cells, which express the TIF2 gene, were however the opposite and consistent with the active transcriptional status; the wild-type and unmethylated primer set amplified Soluble chromatin used in immunoprecipitations had a typical size of p0.5 kb as visualized by gel electrophoresis. Sonicated preparations above this threshold were not used for ChIP analysis. The lysates were immunoprecipitated with a polyclonal antibody to MeCP2 and the gene promoter was detected by PCR using TFPI-2 gene-specific primers, as described in Materials and methods the PCR fragment, but no product was seen with the methylated primers ( Figure 7b ). These data provide unequivocal evidence for the methylation of the CpG islands of the TFPI-2 promoter, and confirm that DNA methylation plays a pivotal role in silencing this important gene in human glioma cells.
Discussion
Human TFPI-2 is a Kunitz-type serine protease inhibitor present in the ECM of endothelial cells (Iino et al., 1998) , fibroblasts (Rao et al., 1995) , and glioma cells (Miyagi et al., 1994) . TFPI-2 transcripts are also abundant in the full-term human placenta, liver, skeletal muscle, heart, kidney, and pancreas (Miyagi et al., 1994; Sprecher et al., 1994) . Owing to this broad distribution, TFPI-2 has been suggested to play a regulatory role in blood coagulation. The presence of this inhibitor in the ECM of gliomas assumes critical importance because of the demonstrated role the matrix metalloproteinases play in the tumor invasion of the normal brain tissue (Rao et al., 1993) . Gliomas are the most common primary tumors of the human central nervous system, and the glioblastomas represent the most malignant and advanced grade tumors of this class. The genetic and epigenetic events involved in glioma progression of gliomas remain poorly defined. We reported that TFPI-2 expression is gradually decreased during glioma progression (Rao et al., 2001) , and that the gene is transcriptionally regulated; the anti-invasive function of TFPI-2 in prostate and lung tumors was also shown (Konduri et al., , 2001a (Konduri et al., , b, 2002 Lakka et al., 2000) . We hypothesized that DNA methylation is the mechanism underlying the absence of TFPI-2 expression in higher grade gliomas, and the several lines of evidence presented here indeed support our notion. The cell lines used, Hs683, a low-grade glioma that is relatively noninvasive and expresses high levels of TFPI-2 mRNA and protein, and SNB19, a glioblastoma that is tumorogenic and highly invasive served as appropriate resources for this study. We showed that inhibition of the DNMT, which maintains the genomic de novo methylation of cytosines, by itself, was able to induce the gene appreciably (Figures 1 and 2) . While TSA, a specific inhibitor of the HDAC, also supported the reactivation of TFPI-2, by itself, the combination of TSA þ 5aC was highly synergistic in inducing the TFPI-2 transcripts and protein. Such a synergism between these two different types of inhibitors has been demonstrated for many genes including the estrogen receptor (Ghoshal et al., 2002) and metallothionein (Yang et al., 2001) , and is consistent with the recently uncovered mechanisms by which methylation regulates gene expression. In this model, regions of methylated DNA adjacent to the promoter sites of genes recruit methyl CpG-binding proteins that in turn associate with large protein complexes containing corepressors and histone deacetylases. The binding of these complexes to DNA leads to a change in the chromatin structure from an active to an inactive form, thereby blocking the assembly of basal transcriptional machinery to the promoter (Kaludov and Wolffe, 2000) .
In line with these mechanisms, we obtained evidence using ChIP assays for the binding of the MeCP2 protein with the repressed promoter in SNB19 cells, and its dissociation following the reactivation of the TFPI-2 gene. In our study, the 5aC þ TSA-treated cells exhibited almost complete derepression (i.e. the gene is transcriptionally active). In this case, the MeCP2 was lost from the promoter (i.e. a weak PCR signal), which we believe enabled efficient transcription of the TFPI-2 gene ( Figure 6 ). Our experiments using 5aC alone demonstrated that methylation, by itself, exerts a repressive influence on TFPI-2 chromatin. These results are consistent with the observations that histone deacetylation may reactivate gene expression only after a certain level of demethylation is achieved (Cameron et al., 1999) . MeCP2 is the best-characterized methyl
Figure 7 MSP of TFPI-2. Primer sets that detected the methylated or unmethylated TFPI-2 promoter sequences in the bisulfitemodified DNA were designed using a computer program. Wild-type primers were used to detect the same sequence in the unmodified DNA; unmethylated (U), methylated (M), or unmodified/wild type (W). (a) Amplification of the bisulfite-treated DNA from the SNB 19 cells and unmodified DNA from the Hs683 cells is shown. Methylated product was detected in SNB19 cells with methylated primers. After demethylation (5aC þ TSA treatments) and reactivation of the gene, no PCR product was seen with the methylated primers. Concomitantly, there was no product with unmethylated primer set in SNB19 cells before drug treatment; after demethylation, the unmethylated primers yielded a fragment of the expected size. (b) In Hs683 cells, unmethylated primer set amplified the same fragment after bisulfite treatment and PCR did not yield a product when methylated primers were used cytosine-binding protein with the ability to bind as little as a single methylated CG nucleotide, but higher number of methylated residues may increase the binding (Lewis et al., 1992) . It is concentrated in the centromeric heterochromatin and associates with the Sin3A histone deacetylase complex, consisting of at least seven proteins including the transcriptional repressor Sin3A and histone deacetylases HDAC1 and HDAC2 (Nan et al., 1998) , thus linking the DNA methylation with histone deacetylation. Histone deacetylation suppresses gene expression by removing acetyl groups from histones, which in turn leads to more compact chromatin that is transcriptionally inactive (Ng and Bird, 2000) . Our chIP assay results showing the loss of MeCP2 from the activated gene (after treatment with 5aC and TSA) clearly indicate the involvement and interplay of the histone deacetylases with the DNA methylation machinery in the re-expression of the TFPI-2 gene (Jones et al., 1998; Nan et al., 1998) in glioma cells. However, the MeCP2 has been shown to repress gene transcription by direct prevention of the assembly of basal transcriptional complexes to the promoter (Kaludov and Wolffe, 2000). We did not test the association of MeCP1 (Ng et al., 1999) , which contains the methylCpG-binding protein 2 (MBD2), the histone deacetylases HDAC1 and HDAC2 with the TFPI-2 promoter, and do not rule out a role for this protein in repressing the TFPI-2 gene. Additional evidence was also obtained by in vitro methylation of the TFPI-2 promoter and transfection of these constructs. Methylation of the promoter is expected to turn off the reporter expression irrespective of whether the endogenous gene is transcriptionally active or silent. Hence, we observed inhibition of reporter activity in both Hs683 and SNB 19 cells after in vitro methylation of the TFPI-2 promoter (Figures 7a,  b) . These results provide strong support that methylation is a prime regulator of TFPI-2 expression. Methylation-sensitive PCR was another direct strategy that we used to show the association of methylated promoter with TFPI-2 repression in SNB19 cells.
Promoter methylation is a frequent event in GBMs affecting multiple genes (e.g. ER, N33, the candidate tumor suppressors P15, P16, and HICI). Our data show that a similar mechanism operates to inactivate the TFPI-2 gene in glioblastoma and higher grade gliomas. Understanding the mechanisms that govern such a grade-specific repression of TFPI-2 during glioma progression, and the details of how exactly methylation curtails TFPI-2 expression will be highly important, particularly because a balance between a protease inhibitor (such as TFPI-2) and its target will determine the tumor characteristics such as adhesion, invasion, and malignancy. TFPI-2 repression could also serve as a useful marker for glioma classification, and provide novel avenues for improving glioma therapy. For example, a restoration of wild-type TFPI-2 expression in glioma cells is likely to induce an anti-invasive effect followed by growth arrest and subsequent modification of the neoplastic phenotype. Therefore, a pharmacological reactivation of the TFPI-2 gene in advanced tumors may lead to useful and exploitable therapeutic strategies.
Materials and methods

Cell cultures and drug treatment
Two human brain tumor cell lines, Hs683, a low-grade noninvasive astrocytoma and SNB19, a highly invasive malignant glioblastoma, studyobtained from the American Type Culture Collection (Manassas, VA, USA) were used in this study. Hs683 and SNB19 cells were grown in Dulbecco's modified Eagle's medium (DMEM). All cultures were supplemented with 1% glutamine, 100 mg/ml streptomycin, 100 U/ml penicillin, and 10% fetal bovine serum (pH 7.2-7.4) and maintained in a humidified atmosphere containing 5% CO 2 at 371C. 5aC was purchased from Sigma (St Louis, MO, USA) and TSA was purchased from Cayman Chemical Company (Ann Arbor, MI, USA). Cells were treated with 5aC (5 mm) for approximately 3 days and subsequently incubated with TSA for 20 h, wherever specified.
Antibodies and Western blot analysis
Anti-MeCP2 rabbit polyclonal antibody was purchased from Upstate Biotechnology (Waltham, MA, USA). SNB19 cells were grown to 80-90% confluence in six-well plates and treated with 5aC, TSA, or 5aC þ TSA. ECM was prepared by lysing the cells with RIPA buffer (Ehrlich et al., 1991) . The total cell lysate was used to detect MeCP2 proteins, and ECM was used to detect TFPI-2 proteins. Briefly, cells were washed three times with PBS and then lysed via incubation with PBS containing 0.5% (v/v) Triton X-100 for 20 min at room temperature. The remaining ECM was washed three times with PBS and another three times with 20 nm Tris-HCl (pH 7.4) containing 100 mm NaCl and 0.1% (v/v) Tween-20. After these washings, no visible cells were left in the dishes as judged by light microscopy. To collect ECM proteins, 200 ml of 1X SDS-PAGE sample buffer was added to each well and cells were agitated for 15-20 min at room temperature. Aliquots (25 ml) of these extracts were assayed for TFPI-2 triplet levels by Western blotting. The membranes were incubated overnight at 41C with anti-TFPI-2 antibody (1 : 3000). After several washes, they were incubated for 1 h with a peroxidase-conjugated secondary antibody (1 : 3000). The immunoreactive proteins were identified using an enhanced chemiluminescence (ECL).
Transfection assays
A measure of 1 Â 10 6 cells (Hs683 and SNB19) were transiently transfected with 1-2 mg of the reporter gene vectors containing methylated or unmethylated TFPI-2 promoter constructs. We used 6 ml of Fugene 6 transfection reagent (Roche Molecular Biochemicals, Indianapolis, IN, USA) for optimal transfection efficiency. PRL-TK (300 ng) (Renilla luciferase) was used as an internal control. After transfection, the cells were washed twice with PBS and lysed with lysis buffer supplied in DLR Assay kit (Promega, Madison, WI, USA), and the luciferase activity was measured as described below. All the treatments were carried out in serum-free conditions. Reporter gene analysis was performed according to the manufacturer's instructions.
Luciferase assays
Luciferase activity was measured with Promega's DLR luciferase assay kit. Briefly, cells were washed twice with PBS and lysed with 100 ml of reporter lysis buffer. The lysate was shaken at room temperature for 10-15 min, after which 20 ml of each cell lysate was mixed with 100 ml of buffer and measured for luciferase activity with a Turner luminometer (Turner Designs, Sunnyvale, CA, USA) over an integration period of 15 s. Values obtained were normalized to PRL-TK levels (Renilla luciferase).
Promoter constructs and in vitro methylation
The wild-type pTF6 construct used in this study has been described previously by Konduri et al. (2002) . From this construct, the promoter region was excised using KpnI and XhoI restriction enzymes, gel purified and incubated with SsssI methylase and then ligated into the PGL-3 basic luciferase reporter vector. The ligated constructs were used directly for transfection. Two reporter gene vectors were used in this study: the PGL-3 basic vector (Promega), which was used to examine TFPI-2 promoter activity, and PRL-TK (Promega), which was used to monitor transfection efficiency.
RNA isolation and RT-PCR
SNB19 cells were grown to 80-90% confluence in 100 mm dishes and treated with 5aC (2.5, 5, and 10 mm), TSA (0.5 mm) and 5aC þ TSA (5 mm and 0.5 mm), respectively. Total cellular RNA was isolated using Trizol (Gibco BRL, Carlsbad, CA, USA) according to the manufacturer's instructions. Total RNA (2 mg) was reverse transcribed using cDNA cycle kit (Invitrogen Corp, Carlsbad, CA, USA) and 1/10 of the reaction was subjected to PCR using TFPI-2 gene-specific primers (forward 5 0 GTC GAC GGA TCC GTT TCC TCA TGC TGT C 3 0 , reverse 5 GTC GAC GGA TCC GTC ATA TTT GCT TTT A 3 0 ) and the following reactions: 941C for 1 min, 601C for 1 min, 721C for 3 min for 35 cycles in a thermocycler (GeneAmp PCR Systems 9700, Applied Biosystems, Foster City, CA, USA). GAPDH (Forward 5 0 CGG AGT CAA CGG ATT TGG TCG TAT 3 0 Reverse 5 0 AGC CTT CTC CAT GGT GGT GAA GAC 3 0 ) PCR with following reactions: 941C for 1 min, 601C for 1 min, 721C for 3 min for 35 cycles in a thermocycler (GeneAmp PCR Systems 9700, Applied Biosystems, Foster City, CA, USA) was used as an internal control. The amplified product was separated electrophoretically on 1.2% agarose gels with ethidium bromide and analysed by photography.
ChIP analysis
SNB19 cells (2 Â 10 6 ) were grown in 100 mm dishes and treated with 5aC, TSA, and 5aC þ TSA as described in an earlier section. The ChIP method was performed as previously described elsewhere (El Osta et al., 2002) . Briefly, cells were harvested, and the proteins were crosslinked to DNA by adding formaldehyde to 1% for 10 min. The cells were then allowed to settle in a 1% SDS buffer followed by sonication in the presence of protease inhibitors. The soluble chromatin fraction was mixed with 5 ml of MeCP2 antibodies, and incubated overnight with rotation. Immune complexes were collected with salmon sperm DNA-protein agarose, washed, and eluted with buffer (1% SDS, 0.1 m NaHCO 3 ). The protein-DNA crosslinks were treated with proteinase K, recovered by phenol-chloroform extraction, and ethanol precipitated. The DNA samples were dissolved in water, and subjected to PCR using TFPI-2 promoter-specific primers for detecting the sequences that interacted with the MeCP2 protein.
MSP
SNB19 cells were treated with 5aC þ TSA (3 days and 20 h, respectively). Genomic DNA was isolated using a DNA extraction kit (Invitrogen, Carlsbad, CA, USA) from SNB 19 and Hs683 parental cells and 5aC þ TSA-treated SNB19 cells. DNA modification was carried out using CpGenome DNA modification kit (Intergen Company) as per the manufacturer's instructions. Primers were designed using CpG Ware software (Serologicals Inc, Norcross, GA, USA). The following primers were used during the PCR reaction. Ampli-Taq Gold PCR master mix was used in the PCR reaction for product amplification (Applied Biosystems, Foster City, CA, USA). 
